Betahistine Use in Pediatric Populations

Evidence Against Use in Pediatric Populations

The American Academy of Otolaryngology-Head and Neck Surgery does not include recommendations for betahistine use in pediatric populations, focusing instead on adult treatment protocols 1
Betahistine's safety profile has been primarily established in adults, with no specific pediatric dosing guidelines available in current clinical recommendations 1
The BEMED trial found that betahistine showed no significant difference compared to placebo in reducing vertigo attacks related to Ménière's disease 2

Betahistine should be used with caution even in adults with asthma and history of peptic ulcer disease, conditions that may also affect pediatric patients 1
The drug is completely contraindicated in patients with pheochromocytoma, making thorough screening necessary before administration to any patient 1

Current guidelines for pediatric medication use specify that none of the currently licensed antihistamines is contraindicated in children 12 years and older, but this refers to H1 antihistamines used for conditions like urticaria, not H3 antagonists like betahistine 3
For pediatric patients with vertigo symptoms, guidelines recommend consulting relevant data sheets before prescribing any medication, and betahistine lacks specific pediatric approval 3

For acute vertigo in pediatric patients, medications with direct antiemetic and anti-vertigo effects are preferred over medications like betahistine that work through vascular mechanisms 2
In pediatric patients requiring chemical restraint or management of acute agitation, guidelines provide specific dosing for various medications including benzodiazepines and antipsychotics, but do not include betahistine 4
When managing pediatric patients with neuropsychiatric conditions that may present with dizziness, guidelines recommend baseline assessments and careful medication selection appropriate for the patient's age 5